SABCS 2023 | Copanlisib and fulvestrant with abemaciclib in HER-, ER+ breast cancer

Cynthia Ma, MD, PhD, Washington University, St. Louis, MO, discusses findings from a Phase I trial (NCT03939897) of copanlisib, a PI3K inhibitor, and fulvestrant with continuous or intermittent abemaciclib in patients with HER-, ER+ breast cancer. The aim of the trial was to determine the recommended Phase II dose (RP2D) of the investigational therapy. Copanlisib and fulvestrant with intermittent abemaciclib were found to be tolerable, where preliminary anti-tumor activity was reported. This interview took place at the San Antonio Breast Cancer Symposium (SABCS) congress in San Antonio, TX.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.